Clinical Trials on Myeloma, Plasma Cell

Total 35566 results

Sidney Kimmel Comprehensive Cancer Center at Johns...
Incyte Corporation

Recruiting

Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients

Myelodysplastic Syndromes | Myeloproliferative Disorders | Multiple Myeloma | Plasma Cell Leukemia | CML | T-cell Prolymphocytic Leukemia | Leukemia, Acute | Myelomonocytic Leukemia, Chronic

United States
Jennifer Eva Selfridge

Recruiting

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Colorectal Cancer | Hodgkin Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma | Chronic Myeloid Leukemia | Plasma Cell Myeloma | Hematologic Malignancy | Rectum Cancer | Myeloproliferative Syndrome

United States
University of Maryland, Baltimore
University of Maryland Greenebaum Cancer Center

Completed

Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Anemia | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease

United States
Aronex Pharmaceuticals

Completed

Antifungal Therapy for Fever and Neutropenia in Patients Receiving Treatment for Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Infection | Multiple Myeloma and Plasma Cell Neoplasm

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)

Terminated

Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease

United States
Uppsala University
Dalarna County Council, Sweden; Uppsala County Council, Sweden

Not yet recruiting

Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma

Myeloma Multiple
Cartesian Therapeutics

Recruiting

Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

Myeloma Multiple

United States
Poitiers University Hospital
Sanofi; Intergroupe Francophone du Myelome

Active, not recruiting

Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma

Multiple Myeloma | Myeloma | Myeloma Multiple

France
Chong Kun Dang Pharmaceutical

Unknown

CKD-581 + Bortezomib + Dexamethasone in Patients With Previously Treated Multiple Myeloma

Myeloma, Multiple

Korea, Republic of
University of Leeds
Karyopharm Therapeutics Inc; Myeloma UK

Withdrawn

Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma (MUKfourteen)

Myeloma Multiple

United Kingdom
Peter MacCallum Cancer Centre, Australia
Janssen, LP

Recruiting

CAR-T Cell Therapy in RelApsed/Refractory Myeloma With ExtrameduLlary Disease - an in Vivo Imaging and Molecular Monitoring Study (CARAMEL)

Extramedullary Myeloma

Australia
PETHEMA Foundation
Adknoma Health Research

Recruiting

Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide

Relapsed Multiple Myeloma

Spain
Cartesian Therapeutics

Completed

Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

Myeloma Multiple

United States
Association for Training, Education, and Research...

Completed

Non-interventional Study on Salvage Auto in Relapsed Myeloma (IFM-2015-03)

Relapsed Multiple Myeloma

France
Washington University School of Medicine

Withdrawn

Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma

Multiple Myeloma | Myeloma-Multiple
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Terminated

Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)

Lymphoproliferative Disorders | Hematologic Diseases | Multiple Myeloma | Acute Lymphoblastic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Plasma Cell Dyscrasia | Myelodysplastic and Myeloproliferative Disorders

United States
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies

Lymphoma | Acute Myeloid Leukemia | Multiple Myeloma
Memorial Sloan Kettering Cancer Center

Recruiting

Pilot Trial of Homebound Stem Cell Transplantation

Plasma Cell Dyscrasia

United States
Ohio State University Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Completed

Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

Multiple Myeloma | Plasma Cell Neoplasm

United States
All4Cure
GlaxoSmithKline

Recruiting

Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma

Multiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma, Refractory

United States
University of Chicago
National Cancer Institute (NCI)

Active, not recruiting

Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma

United States, Canada
Sidney Kimmel Cancer Center at Thomas Jefferson...

Completed

Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma

United States
Michael A. Thompson, MD, PhD
Vince Lombardi Cancer Clinic

Completed

Study of the Immune Response After Vaccination in Multiple Myeloma Patients

Multiple Myeloma | Myeloma, Multiple | Myeloma-Multiple

United States
University of Southern California
National Cancer Institute (NCI); Celgene Corporation

Terminated

Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma

Multiple Myeloma | Plasma Cell Neoplasm

United States
Brenda Cooper, MD

Completed

Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803

Soft Tissue Sarcoma | Acute Myeloid Leukemia | Hodgkin Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma | Chronic Myeloid Leukemia | Myelodysplastic Syndrome | Plasma Cell Myeloma | Rhabdomyosarcoma | Colon Carcinoma | Adenocarcinoma of Rectum | Myeloproliferative Syndromes and other conditions

United States
Lawson Health Research Institute
The Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health System

Active, not recruiting

Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma (RithMM)

Multiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage III

Canada
Ohio State University Comprehensive Cancer Center

Active, not recruiting

Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study

Hematopoietic and Lymphoid Cell Neoplasm | Acute Myeloid Leukemia | Hodgkin Lymphoma | Myelofibrosis | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Plasma Cell Myeloma | Aplastic Anemia | Myeloproliferative Neoplasm | Chronic Myelogenous Leukemia...

United States
Roswell Park Cancer Institute

Completed

Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease

United States
Northside Hospital, Inc.

Terminated

Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm

United States
Institute of Hematology & Blood Diseases Hospital

Unknown

a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients

Multiple Myeloma | Plasma Cell Leukemia | Extramedullary Plasmacytoma | Loss of Chromosome 17p | t(14;16) | t(4;14) | Complex Karyotype | T(14;20) | 1Q21 Amplification

China
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Terminated

506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Institutes of Health (NIH)

Recruiting

Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

Diffuse Large B-Cell Lymphoma | Acute Myeloid Leukemia | Recurrent Hodgkin Lymphoma | Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Myelodysplastic Syndrome | Recurrent Small Lymphocytic Lymphoma | Blastic Plasmacytoid Dendritic Cell Neoplasm | Prolymphocytic Leukemia and other conditions

United States
Mayo Clinic

Completed

Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma

United States
National Cancer Institute (NCI)

Terminated

Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma

Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Celyad Oncology SA
National Heart, Lung, and Blood Institute (NHLBI); Dana-Farber Cancer Institute

Completed

Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands

Acute Myeloid Leukemia | Multiple Myeloma | Myelodysplastic Syndrome

United States
Multiple Myeloma Research Consortium

Not yet recruiting

Horizon Adaptive Platform Trial Evaluating Therapies in RRMM

Refractory Multiple Myeloma | Relapse Multiple Myeloma
Massachusetts General Hospital
Pfizer

Recruiting

Elranatamab in R/R Multiple Myeloma

Multiple Myeloma | Refractory Multiple Myeloma | Relapse Multiple Myeloma

United States
Carl Ola Landgren, MD, PhD
Bristol-Myers Squibb

Recruiting

Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma (Iber-KDd)

Refractory Multiple Myeloma | Relapsed Multiple Myeloma

United States
Cristiana Costa Chase, DO

Not yet recruiting

A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma (COSTA)

Relapsed/Refractory Multiple Myeloma

United States
Pfizer

Recruiting

A Study to Learn How Patients With Triple Class Refractory Multiple Myeloma (TCR-MM) Are Treated in Italian Centers for Blood Related Diseases (MUST)

Refractory Multiple Myeloma | Relapse Multiple Myeloma

Italy
Shenzhen University General Hospital

Recruiting

B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma | Refractory Multiple Myeloma | Relapse Multiple Myeloma

China
Arbeitsgemeinschaft medikamentoese Tumortherapie
Medical University of Vienna; Sanofi; Assign Data Management and Biostatistics... and other collaborators

Recruiting

Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM

Newly Diagnosed Multiple Myeloma

Austria, Greece, Serbia
Zhejiang University
Yake Biotechnology Ltd.

Not yet recruiting

A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma

Refractory Multiple Myeloma | Relapse Multiple Myeloma

China
Multiple Myeloma Research Consortium
Eli Lilly and Company; GlaxoSmithKline; AbbVie; Takeda; Genentech, Inc.; Celgene Corporation and other collaborators

Recruiting

Myeloma-Developing Regimens Using Genomics (MyDRUG) (MyDRUG)

Relapsed Refractory Multiple Myeloma

United States
Amgen

Completed

Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma. (CANDOR)

Refractory Multiple Myeloma | Relapsed Multiple Myeloma

Canada, Belgium, Spain, United States, Korea, Republic of, Australia, Czechia, Taiwan, Hungary, Austria, Romania, Japan, United Kingdom, Greece, Turkey, Bulgaria, France, Russian Federation, Poland
University of Leeds

Completed

Selinexor, Cyclophosphamide and Prednisone in Myeloma (MUKtwelve)

Relapsed or Refractory Multiple Myeloma

United Kingdom

Clinical Trials on Myeloma, Plasma Cell

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations